Rein Therapeutics, Inc. (RNTX): restructuring charge — Aileron terminates ALRN-6924 Phase 1b trial; cuts workforce to 3; explores strategic alternatives

Rein Therapeutics, Inc.

Phase 1b trial showed Grade 4 neutropenia and alopecia; primary endpoint not met; development of ALRN-6924 terminated.
Workforce reduced from 9 to 3 employees; severance costs estimated at $1.0-1.1 million, recorded in Q1 2023.
Company exploring strategic alternatives including M&A, merger, or asset sale; engaged Ladenburg Thalmann as advisor.
No set timetable for strategic review; no assurance any transaction will occur.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Rein Therapeutics, Inc. announced a restructuring with charges of approximately $1.0 to $1.1 million affecting the Company (reduce the Company’s remaining workforce from nine to three employees).

Type: restructuring
Charge: approximately $1.0 to $1.1 million
Affected area: the Company
Headcount: reduce the Company’s remaining workforce from nine to three employees

Exact text from the filing

nine to three employees. The determination to effect the workforce reduction was made in connection with the Company’s decision, further described below, to terminate its Phase 1b breast cancer trial of ALRN-6924 and further development of ALRN-6924. The workforce reduction is designed to reduce the Company’s operating expenses while the Company explores

View on SEC.gov

Browse all restructurings & charges →

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-046516

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.